Development and commercialization of drugs for rare diseases.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: December 2025
This analysis is not yet available in English. Please see the French version.
Leading organizations
Takeda
B
Development and commercialization of innovative medicines in various therapeutic areas, including gastrointestinal diseases, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.
Genethon
B
Research and development of gene therapy medicines for the treatment of rare diseases.
Chiesi SAS
B
Development and marketing of pharmaceuticals in respiratory, neonatology, transplantation, and rare diseases.
Initiatives identified among leaders
Promotion de la santé et allègement de la souffrance des patients
“Chiesi SAS promeut la santé et allège la souffranc...” - Chiesi SASDéveloppement de programmes de responsabilité sociale
“Takeda développe des programmes de responsabilité ...” - TakedaAdoption du statut d'entreprise à mission pour intégrer la responsabilité sociétale dans ses activités
“Adoption du statut d'entreprise à mission pour int...” - Chiesi SAS57% of similar organizations communicate on CSR issues
+3534 initiatives collected from 100 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports